 NEW YORK, Sept. 13, 2021 GLOBE NEWSWIRE -- Y-mAbs Therapeutics, Inc. Y-mAbs or the Company, NASDAQ: YMAB, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that its partner SciClone Pharmaceuticals Holdings Limited SciClone Pharmaceuticals has been granted priority review of the Biologics License Application BLA for DANYELZA naxitamab-gqgk for the treatment of patients with relapsedrefractory high-risk neuroblastoma by the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA. 